Provide feedbackProvide feedback
Home :: Cardiology

Greater CT use in emergency departments to evaluate common chest symptoms has not improved rate of clinically significant diagnoses, study indicates

Thursday, January 26 2012 | Comments
Evidence Grade 0 What's This?

Despite dramatically increased usage of computer tomography (CT) in emergency departments (EDs) to evaluate common chest (CC) symptoms, the proportion of related ED visits associated with a clinically significant diagnosis has decreased, study data suggest. The data were obtained from the National Hospital Ambulatory Medical Care Survey. Two three-year periods were evaluated--from 1997 through 1999 and from 2005 through 2007. Federal hospitals were not included in the survey data, and only...

Despite dramatically increased usage of computer tomography (CT) in emergency departments (EDs) to evaluate common chest (CC) symptoms, the proportion of related ED visits associated with a clinically significant diagnosis has decreased, study data suggest.

The data were obtained from the National Hospital Ambulatory Medical Care Survey. Two three-year periods were evaluated--from 1997 through 1999 and from 2005 through 2007. Federal hospitals were not included in the survey data, and only ED-related data for patients aged at least 15 years were analyzed.

The primary outcome of interest was the proportion of CC symptom-related visits associated with a CT order. Visits with symptoms of chest pain, shortness of breath and labored breathing were identified and coded as a CC symptom-related visit.

Secondary outcomes were clinically significant CC diagnoses, including acute myocardial infarction, acute coronary syndrome, pulmonary embolism (PE) and infarction, heart failure, pneumonia, organism unspecified and unspecified pleural effusion. Incidental findings included diagnoses of intrathoracic lymph nodes, a swelling, mass or lump in the chest, abdominal mass and coin lesion lung.

In all, data were available for 136,751 ED visits during the six years analyzed (53,145 for the earlier period and 83,606 for the later period). A CC symptom-related visit was recorded for 17,098 of the visits. Using these data, the researchers estimated that approximately 11 million CC symptom-related ED visits occurred in the United States each year during the study period, representing 13 percent of all ED visits for patients in the age group analyzed.

Both time periods had similar proportions of CC symptom-related ED visits.

The proportion of CC symptom-related visits associated with a CT order was significantly greater in the later period than in the earlier period for all CC symptoms combined (11.5 percent vs. 2.1 percent) and for each individual CC symptom. Further, not only did the rate of CT ordering increase from the first three-year period to the second three-year period, but it also nearly doubled during the later period, increasing from 8.6 percent in the first six months of 2005 to 15.8 percent in the last six months of 2007.

After adjustments were made for demographic variables, the researchers found that the CC symptom-related ED visits made from 1997 through 1999 were more likely to be associated with a clinically significant diagnosis than were the visits made from 2005 through 2007 (23.6 percent vs. 19.1 percent).

The researchers noted that myocardial infarction was the largest contributing diagnosis in the rate discrepancy between the earlier and the later period.

Of all the ED visits associated with CC symptoms in either time period, less than half of 1 percent were associated with a diagnosis of PE, and the proportion of visits that were associated with a PE diagnosis did not change significantly between the two periods. The percentage of CC symptom-related visits that were associated with an incidental diagnosis also did not change significantly from the earlier to the later period. However, the CC symptom-related visits during the 2005-07 period were significantly more likely than were those during the 1997-99 period to be associated with a clinically nonsignificant diagnosis.

"With increases in the number of nonspecific diagnoses and no improvements in clinically significant diagnoses such as PE and pneumonia among patients presenting with CC symptoms, increased utilization seems to provide little to add in the diagnostic work-up and certainly is not altering treatment in the setting of inappropriate ordering," the researchers commented.

"There are also risks associated with repeated intravenous contrast, and an emotional burden can be placed on a patient being informed about a potential diagnosis of cancer," they added, noting that of the 81 patients (out of 459 who underwent cardiac CT) in whom incidental pulmonary nodules were found, none developed lung cancer after two years of follow-up.

"With the radiation risks associated with CT becoming more apparent, utilization of health care resources from an evidential and public health-based approach is warranted," the researchers concluded.

These data were published in the January/February issue of the Journal of the American Board of Family Medicine.

Latest News

FDA approves label update for Merck's Vytorin to include efficacy data from SHARP trial, does not approve indication for Vytorin, Zetia to help prevent vascular events in patients with CKD Verusmed

Wednesday, January 25 2012 | Comments
Evidence Grade 0 What's This?
The Food and Drug Administration approved an updated label for Merck & Co. Inc.'s Vytorin (ezetimibe/simvastatin) to include study results from the SHARP trial showing that the combination cholesterol therapy lowers LDL cholesterol levels with fewer major vascular events relative to placebo in patients with moderate to severe chronic kidney disease...

Timely adjustment of treatment, improvements in patient self-monitoring associated with improved control of diabetes, heart disease, depression, study data suggest Verusmed

Friday, January 20 2012 | Comments
Evidence Grade 0 What's This?
Timely adjustment of drug therapy and greater self-monitoring by patients are associated with better control of diabetes, coronary heart disease (CHD) and depression, according to findings from a randomized controlled trial.

The trial was conducted to evaluate the effects of a patient-centered, team-based intervention (TEAMcare) on outcomes in patients with diabetes (hemoglobin A1C level of 8.5 percent or greater) or CHD (blood pressure [BP] greater than 140/90 mm Hg or LDL...


Statin use associated with increased risk of diabetes in postmenopausal women, data show Verusmed

Monday, January 16 2012 | Comments
Evidence Grade 0 What's This?
A new analysis of data for postmenopausal women enrolled in the Women's Health Initiative (WHI) contributes to evidence suggesting an increased risk of diabetes associated with statin use.

Researchers assessed the risk of new-onset diabetes associated with statin use among 153,840 postmenopausal women who participated in the WHI and did not have diabetes at baseline. Of these women, approximately 7 percent were taking a statin at the start of the study. Statins included in the...

LoneStar Heart acquires exclusive rights to potential diabetes drug class from UT Southwestern Medical Center Verusmed

Monday, January 16 2012 | Comments
Evidence Grade 0 What's This?
LoneStar Heart Inc. acquired the worldwide, exclusive rights to commercialize a new class of small molecules from the University of Texas Southwestern Medical Center (UT Southwestern).

Researchers with UT Southwestern have shown that these molecules, which are called isoxazoles, restore insulin expression in human pancreas cells and might represent a new approach to the treatment of...



Cardiology Conference Coverage